Skip to content

PTGXPROTAGONIST THERAPEUTICS INC

CUSIP 74366E102 · common stock

6 tracked investors held PROTAGONIST THERAPEUTICS INC (PTGX) at the end of Q3 2026, worth $290M in total. The largest holder was Adar1 Capital Management, with 5.7% of its portfolio. Stanley Druckenmiller sold out of its position this quarter.

Holders · Q3 2026
6
New holders
0
Value held
$290M
Quarter-end price (est.)
$140.89

Investors holding PTGX · Q3 2026

InvestorWeightSharesValueChange
Adar1 Capital Management
ADAR1 Capital Management, LLC
5.71%951,403$134MREDUCE-1.0%
Perceptive Advisors
Perceptive Advisors LLC
2.05%836,579$117.9MREDUCE-14.8%
Ken Fisher
Fisher Asset Management, LLC
0.01%168,373$23.7MREDUCE-1.3%
Joel Greenblatt
Gotham Asset Management, LLC
0.02%65,298$9.2MADD+249.9%
Polen Capital Management
Polen Capital Management LLC
0.03%20,963$3MREDUCE-7.5%
Ron Baron
BAMCO Inc. (Baron Capital)
0.00%16,000$2.3MHOLD

Sold out this quarter

InvestorPrior weightPrior sharesPrior valueChange
Stanley Druckenmiller0.49%208,900$25.6MEXIT

History

QuarterHoldersNewSold outValue heldQuarter-end price (est.)
Q3 2026601$290M$140.89
Q2 2026701$291.7M$122.58
Q1 2026801$277.6M$105.40
Q4 2025900$243.8M$87.34